A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

NCT06016270 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategy

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: hSTC810 400 mg + Paclitaxel
DRUG: hSTC810 800 mg + Paclitaxel

Sponsor

STCube, Inc.